Drugs / SOA101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07055594 | Jul 2025 → Feb 2028 expected | cancer | Shine-On Biomedical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07055594 ↗ |
| Modality | Protein / enzyme biologic | “The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3.” NCT07055594 ↗ |
| Target | HLA-G | “The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3.” NCT07055594 ↗ |